Travere Therapeutics (TVTX) Non-Current Assets (2013 - 2026)

Travere Therapeutics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $162.5 million for Q1 2026.

• Quarterly Non-Current Assets fell 6.94% year-over-year to $162.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $673.3 million (down 5.68% YoY) and the FY2025 annual result came in at $167.6 million, down 5.52% from the prior year.
• Non-Current Assets was $162.5 million for Q1 2026 at Travere Therapeutics, down from $167.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $203.3 million in Q1 2023 and bottomed at $146.6 million in Q3 2023.
• A 5-year average of $179.6 million and a median of $179.7 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets slipped 23.39% — and 2024, when it advanced 22.54%.
• Travere Therapeutics' Non-Current Assets stood at $186.1 million in 2022, then retreated by 7.53% to $172.1 million in 2023, then grew by 3.07% to $177.4 million in 2024, then retreated by 5.52% to $167.6 million in 2025, then fell by 3.05% to $162.5 million in 2026.
• Business Quant data shows TVTX's Non-Current Assets at $162.5 million in Q1 2026, $167.6 million in Q4 2025, and $167.5 million in Q3 2025.